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Abstract – Propofol is a common anesthetic, which is
being investigated as an antidepressant alternative to
electroconvulsive therapy (ECT). Propofol can induce
similar EEG effects to that of ECT, and has also
demonstrated similar improvements in depression
scores. However, propofol dosing is challenging
because patients differ in their required drug doses. A
model of the relationship between administered
propofol and monitored EEG can be used to improve
the accuracy and reliability of this treatment. Our
objective is ultimately to automate processes in
propofol’s dose determination. A summary of patientsystem modeling in anesthesia will be discussed, along
with preliminary results from recent open-label trials.

I.

A recent open-label clinical trial at the University
of Utah [5] investigated propofol’s antidepressant effects,
in which 6 of 10 subjects met the >50% criteria for
improvement in their depression scores (HDRS-24),
while 5 of those 6 met the criteria for remission (HDRS24<10). Propofol demonstrated similar antidepressant
effects to ECT [5] but without the side effects that can be
associated with ECT, such as amnesia [9].

BACKGROUND

Depression impacts approximately 16.1 million
US adults [1]. One third of these patients do not respond
to conventional antidepressants [2]. Electroconvulsive
therapy (ECT) can offer these patients effective relief [3],
but its stigmatizing perception can deter many from
receiving care. ECT’s antidepressant effects have been
attributed to the induced “burst suppression” [4] – an EEG
state of alternating quiescence and bursts that can be
induced by ECT. High concentrations of common
anesthetics, such as isoflurane and propofol, can also
induce burst suppression. Both anesthetics have also
demonstrated antidepressant effects [4,5], along with
other anesthetics such as nitrous oxide (“laughing gas”)
[6] and ketamine [7].

Figure 1. Burst suppression EEG state induced by isoflurane. EEG-based
anesthetic depth monitors usually quantify burst suppression by the “ratio”
between quiescence and bursts over a given epoch. (Kenny 2014) [8]
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Figure 2. Change in depressive symptoms over a series of 10 treatments of
propofol-induced burst suppression. (A) Overall changes in HDRS-24 scores,
(B) HDRS-24 changes scaled to baseline score. (Mickey, Tadler 2018) [5]

If proven effective, propofol might become a
viable therapeutic alternative for many patients with
severe depression and limited treatment options.
Propofol’s neural and antidepressant effects are being
further studied in a randomized controlled trial (see
ClinicalTrials.gov: NCT02935647), along with revised
dosing and administration strategies for propofol.
Propofol-induced burst suppression (PIBS) and
deep anesthesia has already demonstrated utility in
clinical practice. By reducing brain metabolism, it offers
neuroprotection during aneurysm clippings [10], and can
suppress seizure activity [11]. However, the relationship
between propofol dose and induced EEG state is
imprecise, with substantial pharmacokinetic and
pharmacodynamic inter-individual variability [12]
Thus, accurate and reliable dosing of propofol to
induce specific levels of burst suppression is challenging.
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II. PK–PD MODELING

III. OBJECTIVE

The amount of propofol interacting with the
patient’s brain is a time-sensitive function of how
propofol accumulates and decays in the body. Thus,
before relating drug input to EEG response, it is useful to
determine the drug concentrations over the treatment
duration. Unlike anesthesia based on inhaled anesthetics,
the drug concentrations for intravenously delivered
propofol cannot be monitored in real-time. Populationbased models such as the Schnider pharmacokinetic
model [13] can be used to estimate propofol
concentrations, and take into account covariates such as
age, BMI, and sex.

From the open-label trial, we directly observed
challenges in formalizing, executing, and evaluating the
PIBS protocol to treat severe depression. Clinicians had
to “learn” and mentally “map” each patient’s response,
while relying on human intuition to dose propofol and
target a burst suppression ratio (BSR) of 80% for 15
minutes. Variability was observed between patients and
their successive treatments, highlighting the need for
objective, quantitative and individualized guidance for
dosing.
To improve the accuracy and reliability achieving
BSR by PIBS, the utility of pharmacokinetic and
pharmacodynamic (PK–PD) models will be applied and
evaluated.
IV. METHODS

Figure 3. Three-compartment model illustrates the interactions between
compartments and their associated rate constants. ke0 represents the rate
constant for equilibration between plasma and effect-site concentrations.
(Al-Rifai 2016) [14]

The Schnider model uses three compartments
(central, rapid peripheral, slow peripheral) and a series of
rate constants. These constants were derived from clinical
data and govern the overall concentration at the effect-site
compartment: a conceptual compartment that reflects the
accumulation of propofol at the response site (presumably
the brain). Euler’s method was used to implement the
associated differential equations [15].
The concentration domain is only an intermediate
domain, which does not yield insight into how patients
respond to the accumulated propofol. However, it does
offer a much more convenient representation of the
temporal implications of the propofol infusion course,
which is critical to characterize the pharmacodynamic
response to propofol.
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Following IRB approval and patient consent, 10
participants 33.6 ± 9.3 years old and BMI 29.3 ± 5.9
(mean ± standard deviation), received a series of 10
treatments of PIBS over the course of 3 weeks, similar to
a typical treatment series of ECT. BSR was calculated
over 1-minute epochs from a left frontal EEG obtained
using the BIS VISTA Monitoring System (Aspect
Medical Systems, Norwood, MA) and a 4-electrode
sensor (BIS Quatro, Covidien, Dublin, Ireland).
Additional monitoring included EKG, pulse oximetry,
noninvasive blood pressure, respiratory rate, and end-tidal
carbon dioxide.
For each treatment, an anesthesiologist
administered an induction bolus of propofol (2,6diisopropylphenol; Diprivan 1% injectable emulsion;
Fresenius Kabi, Bad Homburg, Germany), along with a
continuous infusion (Medfusion 3500 Syringe Pump,
Smiths Medical, Minneapolis, MN) and additional bolus
doses if needed. Following induction, subjects were
intubated and ventilated to maintain an end-tidal CO2 of
35mmHg.
Propofol dosing was guided by real-time EEG
measurements. Propofol induction doses ranged from
200–600 mg and continuous infusions ranged from 300–
650 mcg/kg/min. Propofol was dosed to target a BSR of
80–100% for 15 minutes, similar to a previous protocol
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studying the antidepressant effects of high-concentration
isoflurane anesthesia [16].
Beyond clinical judgement and expertise no
quantitative references or models were used in this
“manual” approach of propofol dosing.
The recorded propofol infusion courses were
analyzed by using Schnider pharmacokinetic model to
estimate predicted effect-site concentrations over the
course of each subject’s treatment series.
Using MATLAB, the following outlines how
Euler’s method was applied to simplify the computations
required in the Schnider model:
x1 = 0; %initial mass in central compartment
Cp = [0]; %initial plasma concentration
Ce = [0]; %initial effect-site concentration
step = 0.1 %minutes
for n = 1:length(t) %loop over desired duration of simulation
dx1 = [x2*k21 + x3*k31 x1*(k10+k12+k13)]*step + B(n); %central
dx2 = [x1*k12 - x2*k21]*step; %rapid peripheral
dx3 = [x1*k13 - x3*k31]*step; %slow peripheral
dCe = [keo*(Cp - Ce)]*step; %effect-site
nCp = x1/V1; %next Cp
nCe = Ce + dCe; %next Ce
Cp = [Cp nCp]; %updated Cp vector
Ce = [Ce nCe]; %updated Ce vector

Figure 4. Pharmacokinetics of a subject’s 9th treatment. TOP: the predicted
effect-site concentrations determined by the Schnider model, derived from an
infusion time course. BOTTOM: both bolus doses and a 600 mcg/kg/min
propofol infusion can together be represented in time by their drug input rates
over time. The concentration domain (red) accounts for the temporal aspect of
drug dosing.

end

V. RESULTS
Figures 4 through 9 show an example of the
pharmacokinetic and pharmacodynamic analysis and
modeling of one of the subject’s (ID: PROP03) ninth
treatment from the open-label trial. Figure 5 offers further
perspective into how PROP03 compared with other
female subjects, as well as inter-treatment variability in
propofol concentrations.
Pharmacokinetics
During the ninth treatment, PROP03 required 4
boluses of propofol to satisfy the treatment protocol’s
BSR range, as well as a continuous infusion of 600
mcg/kg/min.
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Beyond changes in concentration over each
treatment domain, concentration differences between the
treatments and between the patients were also analyzed.
Given the rapid changes in concentration during
induction, the 10-minutes prior to ending propofol
administration were analyzed to more closely reflect
steady state concentrations. Female subjects (n = 5) and
each of their first nine treatments were examined because
of a wider and more evenly distribution of BMI (30.0 ±
7.5kg m-2) compared to male subjects (28.7 ± 4.7kg m-2).
Figure 5 illustrates our findings and suggests a
correlation with required propofol concentrations to
satisfy the target BSR range and BMI of the subject, given
that the subjects are ordered by increasing BMI, as listed:
PROP04 = 19.4 kg m-2, PROP03 = 25.1 kg m-2, PROP09
= 33.4 kg m-2, PROP02 = 34.2 kg m-2, PROP07 = 37.8 kg
m-2.
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Figure 5. Female subjects (ranked from left to right by increasing weight)
varied widely in their average propofol concentrations to satisfy the desired
BSR range, according to the Schnider model. Average propofol concentrations
were calculated over the 10 minutes before the propofol infusion was stopped.
The boxplot highlights both inter-patient variability and inter-treatment
variabilities in the concentration domain.

Figure 6. The corresponding monitored BSR output for PROP03’s 9th
treatment of propofol. Given experience from the previous 8 treatments to
gauge the subject’s response and sensitivity to propofol, the target BSR range
(80-100% for 25 minutes) was well satisfied by the anesthesiologist.

Pharmacodynamics
Pharmacodynamic modeling seeks to relate the
estimated concentrations to the monitored effect, in our
case: the BSR output reported by the BIS Monitor (oneminute averages), which is shown in Figure 6. Upon the
initial bolus of propofol, BSR rapidly increases as brain
activity becomes suppressed, and rapidly decreases as
brain activity recovers and propofol is eliminated from the
subject’s body.
Figure 7 illustrates the relationship of a
pharmacodynamic model of PROP03’s ninth treatment.
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Figure 7. BSR outputs by the BIS Monitor are plotted against the estimated
effect-site concentrations, derived from the infusion data. The data was fit
according to a sigmoidal curve, with Hill and EC50 coefficients of 13 and 12.5
(mcg/mL). Over the duration of the treatment, the plot’s general trend is to
circulate counter-clockwise toward returning to lower concentrations, during
emergence and recovery.
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VI. DISCUSSION
As a retrospective analysis of data that was originally not
collected with a pharmacokinetic/pharmacodynamic
analysis in mind, the conclusiveness of the results is
limited in a number of ways.
Time synchronization: Although updated drug
inputs (see Figure 4) and EEG outputs (see Figure 5) have
been gathered for all patients (n = 10) and all treatments
(m = 99), synchronizing the clocks between the BIS
monitor and clinical administration of propofol was not
adequately conducted, nor was a major research priority.
Assumptions were required to force-fit potential models
of how BSR related to predicted effect-site
concentrations.

Figure 8. Plot of multiple predicted effect-site concentrations with different
ke0s (Schnider in red, Sepúlveda in green, and Marsh original in blue). Altering
the ke0 value of a pharmacokinetic model will alter the rates of accumulation
and decay in the effect-site compartment. This directly relates to changes in the
“time to peak effect” and alignment in the eventual pharmacodynamic model.
(Sepulveda 2018) [17]

Time resolution is another factor that required
assumptions parameterizing the PK–PD models. The
bolus and infusion data were recorded in minute intervals,
while only the averaged BSR could be exported every
minute. Assumptions had to be made about how long each
bolus was administered for, and that they were
administered at the beginning of each minute interval.
A common consequence that can occur from poor
time synchronization and resolution is hysteresis: a
phenomenon in which a clinical response (e.g. BSR)
depends on its past trend of propofol concentration
changes, yielding multiple effects associated with the
same propofol concentration.
Notably, hysteresis can also result from a ke0
pharmacokinetic parameter that is not optimized for the
individual patient. Once the time synchronization and
time resolution has been eliminated as a source of the
hysteresis loop, optimizing the ke0 constant, i.e., the
estimated “time to peak effect” (see Figure 8) for its
effect-site compartment, is a way to collapse a hysteresis
loop (see Figure 9) and estimate the patientindividualized ke0 parameter.
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Figure 9. Upon adjusting the ke0 value from 0.456 min -1 (value determined
by Schnider) to 0.1 min-1 (suggests longer time to peak effect), the plot’s
hysteresis loop visually collapses. Compare with Figure 6. This difference can
offer much utility in future PK–PD of subjects.

Significance
Improving the accuracy and reproducibility of
this propofol-based antidepressant therapy will directly
reduce potential confounding variables impacting the
clinical effect of propofol. As reported by Mickey, Tadler,
et al. [5], subjects experienced a variety of degrees and
durations of burst suppression. Subjects receiving lower
degrees and duration of burst suppression within the 80100% BSR range tended to demonstrate greater
improvements in their depression scores [5]. Over the 10treatment series, different clinicians administered the
treatment, with presumably different approaches to
dosing. Standardizing the control of patient EEG
dynamics through individualized PK-PD models might
reduce the impact of these factors.
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Given the treatment’s high propofol doses, safety
is also an important concern. Individualized PK-PD
modeling might help guide clinicians to identify the
necessary doses and timing in a quantitative fashion. This
also includes when and how to step down and taper the
propofol infusion to achieve a desired time of PIBS.
Closed-loop control advances in anesthesiology
can benefit space mission personnel through more
independent and technological means of clinical care,
where expertise may be limited. For example, without a
formally trained anesthesiologist, an automated total
intravenous anesthesia (TIVA) device can still help
provide treatment options.

More updates will be shared once the blinded
study has concluded and proper due diligence has been
conducted.
VII.

FUTURE WORK

Extensive literature on PK–PD modeling exists
and can be directly applied to a follow-up trial
investigating propofol’s neural and antidepressant effects.
Adaptively
modeling
the
patient-individualized
relationship between drug input and BSR output may
allow improved dosing to better target the desired EEG
response. This would allow to augment the clinician’s
intuition by providing a model-based tool to individualize
propofol dosing.

Follow-on Clinical Trial
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